Safety and efficacy of pralatrexate combined with bortezomib in elderly patients with relapsed or refractory peripheral T cell lymphoma

Trial Profile

Safety and efficacy of pralatrexate combined with bortezomib in elderly patients with relapsed or refractory peripheral T cell lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Bortezomib (Primary) ; Pralatrexate (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Jul 2016 New trial record
    • 01 Jul 2016 Results published in the Journal of Korean Medical Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top